




When your child has been diagnosed with ADHD



IMPORTANT SAFETY INFORMATION

Quillivant XR® (methylphenidate HCI) and QuilliChew ER® (methylphenidate HCI) are federally controlled substances (CII) because they can be a target for people who abuse prescription medicines or street drugs. Quillivant XR and QuilliChew ER have a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep the medicines in a safe place to prevent abuse and misuse. Never give your Quillivant XR or QuilliChew ER to anyone else because it may cause death or harm them. Selling or giving away these medicines may harm others and is against the law.



ADHD is one of the most common neurodevelopmental disorders of childhood¹. According to a 2016 study in the US, among children aged 2-17:

~9% have ever had a diagnosis of ADHD²

~62% of those with current ADHD take medication to manage symptoms²

But finding the right medication can be difficult. A recent study found:

~60% of children and adolescents changed ADHD treatments over a 12-month period³

As the parent of a child with ADHD, you know how important consistency is to their daily routine.⁴

Learn more in this brochure about **Quillivant XR** (methylphenidate HCl) and **QuilliChew ER** (methylphenidate HCl) — two ADHD medications that work with your child's unique profile to provide consistent symptom control you can count on.

WHAT ARE QUILLIVANT XR AND QUILLICHEW ER?

Quillivant XR and QuilliChew ER are central nervous system stimulant prescription medicines. Quillivant XR is a liquid medicine that you take by mouth. QuilliChew ER is a chewable tablet.

Quillivant XR and QuilliChew ER are used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Quillivant XR and QuilliChew ER may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if Quillivant XR or QuilliChew ER are safe and effective in children under 6 years of age.









TWO FORMULATIONS to meet your child's specific needs.

ONE UNIQUE TECHNOLOGY to work with your child's unique profile.



Continuous release through the most important parts of the day^{5,6,7}



Consistent, smooth drug delivery^{5,6,7}



Predictable, long-lasting symptom control^{6,7}

How does our technology work?

A special coating on each drug molecule **protects** methylphenidate until it's ready to be released - so differences in your child's metabolism or changes in their diet don't affect how the medication is released through the day.^{5,8}

IMPORTANT SAFETY INFORMATION (cont'd)

Your healthcare provider should check you or your child's risk for abuse, misuse, and addiction before starting treatment with Quillivant XR or QuilliChew ER and will monitor you or your child during treatment. Tell your physician if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Quillivant XR and QuilliChew ER should not be taken if you or your child are allergic to methylphenidate hydrochloride, or any of the ingredients in these medicines, or are taking or have taken within the past 14 days an antidepression medicine called a monoamine oxidase inhibitor or MAOI.

Meet Quillivant XR (methylphenidate HCI) oral solution



Helps control symptoms from morning through the day⁷

Continuous 12-hour symptom control⁷

• Lasting improvement in attention and behavior⁷

Consistent Medication Delivery

- Continuous, smooth release of methylphenidate throughout the day⁵
- Release not affected by diet or metabolism^{5,8}

IMPORTANT SAFETY INFORMATION (cont'd)

The following have been reported with the use of methylphenidate hydrochloride and other stimulant medicines:

- Heart-related problems:
 - Sudden death in patients who have heart problems or heart defects
 - Stroke and heart attack in adults
 - Increased blood pressure and heart rate
 - Your healthcare provider should check your or your child's blood pressure and heart rate regularly during treatment with Quillivant XR or QuilliChew ER (methylphenidate HCI)
- Mental (psychiatric) problems:
 - New or worse behavior and thought problems
 - New or worse bipolar illness
 - May cause new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms
- Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud's phenomenon):
 - Fingers or toes may feel numb, cool, painful, or may change color from pale, to blue, to red

Call your healthcare provider right away if you or your child have any:

- Heart-related symptoms such as chest pain, shortness of breath, or fainting
- New or worsening mental (psychiatric) symptoms or new manic symptoms
- Signs of unexplained wounds appearing on fingers or toes while taking Quillivant XR or QuilliChew ER





Personalized dosing in a long-acting liquid⁹

Liquid Quillivant XR (methylphenidate HCI) allows your doctor to adjust the dose, up or down, weekly, in amounts of 2 to 4 mL.⁹

- Quillivant XR comes with an oral dosing dispenser to help you measure the correct amount of medication
- Quillivant XR can be taken with or without food
- Take Quillivant XR exactly as prescribed and remember that you MUST shake the bottle vigorously for at least 10 seconds prior to each use



Please see Instructions for Use in the accompanying Full Prescribing Information in pocket of this brochure for specific instructions on how your child should take Quillivant XR.

Or visit <u>www.trisadhd.com/quillivant-xr/taking-quillivant-xr/</u>

IMPORTANT SAFETY INFORMATION (cont'd)

Quillivant XR or QuilliChew ER may not be right for you or your child. Before starting Quillivant XR or QuilliChew ER (methylphenidate HCI) tell your or your child's health care provider about all health conditions (or a family history of) including:

- · Heart problems, heart disease, heart defects, or high blood pressure
- mental problems including psychosis, mania, bipolar illness, or depression

Meet QuilliChew ER (methylphenidate HCI) tablets



When tablets are the preferred option for your child

Effective control of symptoms⁶

- Works through the most important parts of the day⁶
- Lasting improvements in attention and behavior⁶

Consistent Delivery — chewed or swallowed¹⁰

- Continuous, smooth release of medication⁵
- Release not affected by diet or metabolism^{5,8}

IMPORTANT SAFETY INFORMATION (cont'd)

Quillivant XR (methylphenidate HCI) or QuilliChew ER may not be right for you or your child. Before starting Quillivant XR or QuilliChew ER tell your or your child's health care provider about all health conditions (or a family history of) including (cont'd):

- circulation problems in fingers and toes
- have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness)
- have or had repeated movements or sounds (tics) or Tourette's syndrome, or have a family history of tics or Tourette's syndrome
- phenylketonuria (PKU). QuilliChew ER extended-release chewable tablets contain phenylalanine as part of the artificial sweetener, aspartame. The artificial sweetener may be harmful to people with PKU or who are allergic to phenylalanine.
- if you are pregnant or plan to become pregnant. It is not known if Quillivant XR or QuilliChew ER will harm the unborn baby. There is a pregnancy registry for females who are exposed to QuilliChew ER during pregnancy. The purpose of the registry is to collect information about the health of females exposed to Quillivant XR or QuilliChew ER and their baby. If you or your child becomes pregnant during treatment with QuilliChew ER, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or visit https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/
- if you are breastfeeding or plan to breast feed. Quillivant XR or QuilliChew ER passes into your breast milk. You and your healthcare provider should decide if you will take QuilliChew ER or breastfeed.



Personalized dosing for your child

QuilliChew ER (methylphenidate HCI) should be taken by mouth once in the morning.

- Can be chewed or swallowed whole¹⁰
- · Can be taken with or without food

11 dosing options¹¹

- The 20-mg and 30-mg tablets are scored¹¹
 - Scored tablets can be divided into equal halves to allow additional dosing options and to achieve the specific dose that is recommended by your healthcare provider¹¹
 - The 20-mg tablet can be split into 10-mg equal halves, and the 30-mg tablet can be split into 15-mg equal halves¹¹
 - The 40-mg tablet is not scored¹¹



Or visit www.trisadhd.com/quillichew-er/taking-quillichew-er/

IMPORTANT SAFETY INFORMATION (cont'd)

Do not start any new medicine while taking Quillivant XR (methylphenidate HCI) or QuilliChew ER without talking to your healthcare provider first.

What should I avoid while taking Quillivant XR or QuilliChew ER?

Quillivant XR and QuilliChew ER should not be taken with MAOI medicines or if you stopped taking an MAOI in the last 14 days. Do not drink alcohol while taking Quillivant XR or QuilliChew ER. This may cause a faster release of your methylphenidate dose.





Eligible patients pay as little as \$25 each month*

Tris Pharma is here to help support you as you get your child started on medication.

Ask your doctor for your own co-pay card.

Learn how you can pay as little as \$25 for your prescription at trisadhd.com

* Terms and conditions apply. Card issue is subject to eligibility. Visit https://www.trisadhd.com/savings-and-support/ for details.

IMPORTANT SAFETY INFORMATION (cont'd)

Quillivant XR (methylphenidate HCI) or QuilliChew ER (methylphenidate HCI) may cause serious side effects, including:

• See "What is the most important information I should know about Quillivant XR or QuilliChew ER?" for information on reported heart and mental problems.

Other serious side effects include:

- New or worsening tics or worsening Tourette's syndrome. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette's syndrome during treatment with Quillivant XR or QuilliChew ER.
- Painful and prolonged erections (priapism) have occurred with methylphenidate. If you or your child develop
 priapism seek medical help right away. Because priapism can cause long lasting damage, it should be
 checked by a health care provider right away.
- Slowing of growth (height and weight) in children. Children should have their height and weight checked often during treatment with Quillivant XR or QuilliChew ER. Quillivant XR or QuilliChew ER treatment may be stopped if your child is not gaining weight or height.
- Eye problems (increased pressure in the eye and glaucoma). Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.







TWO FORMULATIONS to meet your child's specific needs.

ONE UNIQUE TECHNOLOGY to work with your child's unique profile.

- Efficacy through the most important parts of the day^{6,7}
- Lasting improvement in attention and behavior^{6,7}

IMPORTANT SAFETY INFORMATION (cont'd)

Most common side effects include:

- Decreased appetite - Indig

- Indigestion

- Dizziness

- Increased blood

pressure

- Trouble sleeping

- Stomach pain

- Irritability

- Nausea

- Weight loss

- Mood swings

- Vomiting

Anxiety

- Fast heart beat

These are not all the possible side effects of Quillivant XR (methylphenidate HCI) and QuilliChew ER (methylphenidate HCI).

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.





Consistent ADHD medication delivery⁵ Effective ADHD symptom control^{6,7}

Eligible patients pay as little as \$25 each month*

Visit trisadhd.com

References: 1. CDC. What is ADHD. https://www.cdc.gov/ncbdd/adhd/facts.html. 2. Danielson M. Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016 *J Clin Child Adolesc Psychol*. 2018; 47(2): 199-212. doi:10.1080/15374416.2017.1417860. 3. Schein J, Childress A, Adams J, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A. Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysis. *BMC Psychiatry*. 2022 Aug 18;22(1):555. 4. The World Federation of ADHD guide [electronic resource] / Editors, Luis Augusto Rohde... [et al.]. - Porto Alegre: Artmed, 2019. 5. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 20. 6. Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attentiondeficit/ hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2017;27(8):690-699. 7. Wigal SB, Childress AC, Belden HW, Berry SA. NWPO6, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. *J Child Adolesc Psychopharmacol*. 2013;23(1):3-10. 8. Powell JJ, Greenfield SM, Thompson RP. Concentrations of metals in gastric juice in health and peptic ulcer disease. *Gut*. 1992;33(1):3-10. 8. Powell JJ, Greenfield SM, Thompson RP. Concentrations of metals in gastric juice in health and peptic vlcer disease. *Gut*. 1992;33(1):3-10. 8. Powell DR. Relative bioavailability of methylphenidate extended-release chewable tablets chewed versus swallowed whole. *Clin Ther*. 2018;40(5):733-740. 11. QuilliChew ER [package insert]. Tris Pharma, Inc., Monmouth Junction, NJ.

